news

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

09.08.2023

BridgeBio Pharma to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

09.07.2023

BridgeBio Pharma Announces Positive Feedback from the U.S. FDA and EU EMA on the Regulatory Path for a Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

09.06.2023

BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023

08.27.2023

BridgeBio Pharma to Present Detailed Results from the Phase 3 ATTRibute Study in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) at European Society of Cardiology (ESC) Congress 2023

08.24.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

08.04.2023

BridgeBio Pharma Reports Second Quarter 2023 Financial Results and Business Update

08.03.2023

BridgeBio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-girdle Muscular Dystrophy Type 2I (LGMD2I/R9) Based on Glycosylated Alpha-dystroglycan (⍺DG) Levels and Announces First Patient Dosed in FORTIFY Phase 3 Study

07.31.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

07.18.2023

BridgeBio announces consistently positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)

07.17.2023

BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023

07.14.2023

Burjeel Holdings to Launch Rare Disease Research & Development Project ‘NADER’ in Partnership with US-based BridgeBio Pharma

07.12.2023

BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference

06.20.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06.13.2023

BridgeBio Pharma to Present Updated Six Month Results from its Phase 2 Cohort 5 Study of Infigratinib in Achondroplasia in a Late Breaker Oral Presentation at the Endocrine Society (ENDO) 2023 Annual Conference

06.08.2023

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

05.22.2023

BridgeBio Pharma to Present Updated Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

05.15.2023

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05.11.2023

BridgeBio Pharma Reports First Quarter 2023 Financial Results and Business Update

05.04.2023

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference

04.27.2023

news

Catch up on news from BridgeBio and our pipeline developments. Follow us on LinkedIn, Twitter, and Facebook to keep up with all of the latest news.

news archive

icon icon